CVKD
NASDAQCadrenal Therapeutics Inc.
Price$4.19+0.13 (+3.08%)
03:30 PM07:15 PM
News · 26 weeks45-11%
2025-12-142026-06-07
Mix2490d
- SEC Filings13(54%)
- Insider5(21%)
- Other4(17%)
- Dividends2(8%)
Latest news
25 items- INSIDERChairman, CEO and Interim CFO Pham Quang X sold $93,294 worth of shares (22,385 units at $4.17) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 150,839 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- INSIDERCEO and Chairman Pham Quang X sold $36,209 worth of shares (8,285 units at $4.37) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 173,224 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- PRCadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering EventLead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential 12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is a potential target for therapy and prevention of cancer Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support
- INSIDERCEO and Chairman Pham Quang X sold $3,075 worth of shares (652 units at $4.72) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 181,509 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- INSIDERCEO and Chairman Pham Quang X sold $69,451 worth of shares (12,763 units at $5.44) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 182,161 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- INSIDERCEO and Chairman Pham Quang X sold $6,629 worth of shares (1,165 units at $5.69) as part of a pre-agreed trading plan, decreasing direct ownership by 0.59% to 194,924 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- PRCadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. Company Webcast The webcast presentation will take place at 9:30 a.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2026/ or directly at https://app.webinar.net/DxpqArQk70e. The webcast will also be avai
- SECSEC Form 144 filed by Cadrenal Therapeutics Inc.144 - Cadrenal Therapeutics, Inc. (0001937993) (Subject)
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECSEC Form 10-Q filed by Cadrenal Therapeutics Inc.10-Q - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- PRCadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDAPONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today reported its financial results for the first quarter ended March 31, 2026, and provided a corporate update highlighting continued progress in its CAD-1005 program for HIT. The Company has now received the official minutes from its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), which provided guidance on key elements of the planned pivotal Phase 3 registration trial for CAD-1005, Cadrenal's investigational first-in-class 12-lipoxygenase (12-
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- PRCadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy PONTE VEDRA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today announced a major regulatory milestone after successfully completing its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) and receiving guidance on key elements of the Phase 3 pivotal trial for CAD-1005, the Company's inv
- SECSEC Form EFFECT filed by Cadrenal Therapeutics Inc.EFFECT - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECSEC Form 424B3 filed by Cadrenal Therapeutics Inc.424B3 - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECSEC Form S-3 filed by Cadrenal Therapeutics Inc.S-3 - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECSEC Form D filed by Cadrenal Therapeutics Inc.D - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECSEC Form 424B5 filed by Cadrenal Therapeutics Inc.424B5 - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECSEC Form 10-K filed by Cadrenal Therapeutics Inc.10-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- PRCadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA MeetingPONTE VEDRA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update highlighting recent progress across its CAD-1005 program for HIT and broader 12-LOX inhibitor platform. The update reflects continued progress for CAD-1005, Cadrenal's first-in-class 12-LOX inhibitor for suspected heparin-induced thrombocytopenia (HIT), including completion of its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administra
- PRLife Sciences Virtual Investor Forum Presentations Now Available for Online ViewingNEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
CVKD FAQ
6 questionsWhere does CVKD stock trade?
Cadrenal Therapeutics Inc. (CVKD) is listed on NASDAQ.What sector and industry is CVKD in?
Cadrenal Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Cadrenal Therapeutics Inc. go public?
Cadrenal Therapeutics Inc. (CVKD) completed its IPO in 2023.What are analysts saying about CVKD?
Cadrenal Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Noble Capital Markets: Outperform with a $400.00 price target on 2023-12-18. Recent price targets cluster around $400.00.What companies are similar to CVKD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CVKD side-by-side with any of them on Quantisnow.How can I track CVKD on Quantisnow?
Quantisnow aggregates Cadrenal Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CVKD to receive live email and push alerts on every new disclosure.